Tivic Health Systems, Inc. (TIVC)
| Market Cap | 4.03M +34.8% |
| Revenue (ttm) | n/a |
| Net Income | -8.88M |
| EPS | -7.68 |
| Shares Out | 2.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 352,142 |
| Open | 1.300 |
| Previous Close | 1.330 |
| Day's Range | 1.230 - 1.400 |
| 52-Week Range | 0.722 - 6.950 |
| Beta | 1.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About TIVC
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in Fremont, California.
Financial Performance
Financial StatementsNews
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds I...
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th
SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has been selected to present at the U.S. Departme...
Tivic Health Systems Transcript: Emerging Growth Conference 91
The company is advancing late-stage immune therapies, with Entolimod leading in ARS and neutropenia. Phase III data supports regulatory filings, and government partnerships may enable stockpile inclusion. Key milestones are expected within 18-24 months.
Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod
SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for Informa...
Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference
Presentation will Cover Recent Corporate Milestones Including Securing Agreement with NIAID SAN ANTONIO, TX / ACCESS Newswire / March 27, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a clinical-s...
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome
Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study SAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems...
Tivic Health Systems Earnings Call Transcript: Q4 2025
Pivoted to immunotherapy, exited legacy businesses, and acquired in-house manufacturing. Operating expenses rose with the biopharma launch, but cash position improved. Positioned for growth in oncology and biodefense markets, with significant financing secured.
Tivic Reports Full Year 2025 Results
Completes Strategic Transformation into an Immunotherapy Company and Continues to Advance Entolimod Platform Toward Potential Funding Partnerships Conference Call to be Held Today at 1:30 PM PT / 4:30...
Tivic Health CEO Letter to Shareholders
SAN ANTONIO, TX / ACCESS Newswire / March 24, 2026 / Tivic Health Systems (Nasdaq:TIVC) Dear Valued Shareholders, As I assume the role of Chief Executive Officer at Tivic, my immediate priority is to ...
Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET
SAN ANTONIO, TX / ACCESS Newswire / March 20, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it will report its year-end financial resul...
Tivic Health Systems Transcript: EGM 2026
The meeting detailed a transformative acquisition of manufacturing assets, enabling in-house production and the launch of Velocity Bioworks as a CDMO. Strategic plans focus on accelerating Entolimod's commercialization, expanding revenue streams, and leveraging new capabilities for both internal and third-party clients.
Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma
SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC) ("Tivic" or the "Company"), a late-stage immunotherapeutics company, today announced that its Board of Di...
Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10
Initial presentation on January 26, 2026 s howcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS ...
Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting
January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure BARDA has requested a follow-up meetin...
Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference
CEO Presentation to Include Updates and Further Information on the Following Topics: Entolimod Cell Line Verification Success; 200x Manufacturing Scale-Up with Reproducible Quality; BARDA TechWatch En...
Tivic Health Systems Transcript: Emerging Growth Conference 89
A major transformation has positioned the company as a biopharma with late-stage assets, notably Entolimod, targeting both acute radiation syndrome and oncology. Manufacturing is now in-house, with strong government engagement and up to $75 million in new financing.
Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference
Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™ FREMONT, CA / ACCESS Newswire / January 20, 2026 / Tivic Health® Systems, Inc. (NAS...
Tivic Health Systems Transcript: Investor Update
A major acquisition enabled in-house manufacturing, accelerating drug development and reducing costs while launching Velocity BioWorks as a new revenue-generating CDMO. Positioned for rapid growth, the company expects significant value creation and government engagement in 2026.
Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing o...
Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines
Conference Call to be Hosted on Monday, January 12 at 1:30 PM PT/4:30 PM ET FREMONT, CA / ACCESS Newswire / January 8, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics...
Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package
Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP inclu...
Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome
Meeting with Radiological and Nuclear Medical Countermeasures Program FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage therapeutics company, ...
Tivic Reports Third Quarter 2025 Financial Results
Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified immun...
Tivic Health Systems Earnings Call Transcript: Q3 2025
Strategic transformation advanced with a shift to biologics, highlighted by Entolimod's clinical progress and government engagement. Q3 saw higher R&D spending, a widened net loss, and improved cash position, with consumer device operations wound down.
Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)
The study demonstrated that personalizing the stimulation parameters to each user dramatically enhanced autonomic effects FREMONT, CA / ACCESS Newswire / November 13, 2025 / Tivic Health Systems, Inc....